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In a recently developed strategy for the cellular immunotherapy of malignant diseases, the advantages of antibody-based targeting and cell-mediated cytolysis have been combined by grafting effector cells with a chimeric receptor that binds to a tumor-associated antigen. [1] [2] [3] [4] [5] The antigen-binding domain of the receptor is composed of a single-chain antibody fragment (scFv) derived from the heavy (VH) and light (VL) chain variable regions of a monoclonal antibody (mAb). The intracellular signalling domain is derived from the cytoplasmic part of a membrane-bound receptor involved in cellular activation. After grafting cytotoxic T cells with the chimeric receptor, an antigen-specific and MHC-unrestricted cellular immune response is directed to cells expressing the particular mAb-defined antigen (for review, Refs 6 and 7).
Due to xenogeneic parts of the chimeric receptor, the efficacy in the therapy of malignant diseases, however, will be negatively influenced by the potential of a hostversus-graft reaction. In addition, soluble antigen frequently present in high concentrations in the serum of cancer patients will block the receptor of grafted effector cells thus preventing tumor cell recognition and antigendriven cellular activation upon specific receptor crosslinking. 6, 8 This limitation so far restricts the chimeric receptor approach to those patients with very low amounts of soluble antigen unlikely to prevent effector cell-tumor cell interaction. Malignant tumors, however, that express carcinoembryonic antigen (CEA) are frequently accompanied by high serum concentrations of soluble CEA. 9 In this particular situation the application of the chimeric receptor-based strategy requires a receptor whose tumor cell recognition and effector cell activation is not affected by soluble antigen.
To address this issue we constructed an anti-CEA chimeric T cell receptor whose antigen binding domain has preferential binding specificity for the membranebound form of CEA and which entirely consists of humanized domains. The antigen-binding domain is derived from the humanized mAb humBW431/26 that preferentially binds to membrane-bound CEA and does not react with other members of the CEA family. The reactivity of humBW431/26 is restricted to malignant and premalignant tissues whereas no reactivity with normal tissues was found apart from a low intrinsic reactivity with the luminal part of the colon mucosa. [10] [11] [12] [13] To obtain a chimeric T cell receptor we fused the DNA coding for the anti-CEA single chain antibody fragment (scFv) in frame to the CH2/CH3 domains of the human IgG1 14 and the transmembrane and intracellular domain of the ␥-signalling chain derived from the Fc⑀RI␥-receptor. 2 The DNA coding for the chimeric receptor is expressed under control of the RSV LTR after transfection into the murine T cell line MD45. We obtained 35 colonies out of 67 transfected colonies that secreted high amounts of IL-2 upon co-culture with CEA + tumor cells as tested by ELISA. From these colonies, we established subclones by limiting dilution procedures. A typical clone was selected and further analyzed in detail. FACS analyses revealed that the cell clones specifically react with the antihumBW431/26-scFv idiotypic mAb BW2069/36 13 and with an anti-human IgG1 antibody directed to the CH2/CH3 domain of the receptor. Western blot analysis utilizing the anti-human IgG1 antibody shows under non-reducing conditions (Figure 1, lanes 1-4) a protein band of about 150 kDa whereas under reducing conditions ( Figure 1, lanes 5-8) a band of about 75 kDa was found. The 75-kDa band correlates with the predicted size of the monomeric, the 150 kDa band with the size of the homodimeric receptor. Since exclusively the 150 kDa band is detected under non-reducing conditions, we conclude that the human CH2/CH3 IgG domains facilitate IgG like homodimerization of the receptor molecules.
To test whether receptor grafted T cells which equipped the chimeric receptor are activated by the anti-BW431/26 idiotypic antibody and immobilized CEA, respectively, we assayed by ELISA induction of IL-2 secretion of transfected cells into the culture supernatant. MD45 T cell clones transfected with the humBW431/26-CH2/CH3-␥ receptor and untransfected MD45 cells, respectively, were incubated in microtiter plates coated with the anti-BW431/26 idiotypic mAb BW2064/36 13 or, for control reasons, with the anti-idiotypic mAb 9G10 with specificity for the anti-CD30 mAb HRS3. 15 As shown in Figure 2a , incubation of receptor grafted cells with immobilized anti-idiotypic BW2064/36 antibody resulted in increased IL-2 secretion whereas incubation with an immobilized, isotype matched anti-idiotypic control antibody did not. Incubation of the anti-CEA receptor- bation with CEA + or with CEA − tumor cells. This demonstrates that the chimeric anti-CEA receptor specifically triggers cellular cytotoxicity after specific binding to membrane-bound CEA.
Figure 4 Specific cytotoxicity of MD45 cells grafted with the humBW431/26-CH2/CH3-␥ receptor. Cytotoxicity of transfected and non-transfected MD45 T cells to target cells was measured by time
The efficacy of the immunotherapeutic approach in targeting effector cells by grafted chimeric receptors with an antibody-derived antigen-binding domain will be substantially reduced by soluble antigen that is frequently present in high concentrations in the serum of cancer patients 6, 8 and may block the receptor. We therefore asked whether soluble CEA may interfere with binding of the chimeric receptor to membrane-bound antigen and cellular activation of receptor grafted T cells. HumBW431/26-scFv-CH2/CH3-␥ receptor transfected MD45 T cells were incubated with increasing amounts of soluble CEA and of the anti-BW431/26 idiotypic mAb BW2064/36, respectively, and IL-2 secretion was monitored. As illustrated in Figure 5a , soluble CEA, in concentrations of up to 25 g CEA/ml did not activate anti-CEA receptor-grafted T cells, whereas immobilized CEA efficiently triggered IL-2 secretion (see Figures 2b and  3b) . In contrast, after addition of the anti-humBW431/26 idiotypic mAb secretion of low amounts of IL-2 was recorded which was strongly enhanced after crosslinking of the anti-idiotypic mAb with an anti-mouse IgG mAb. For control, grafted MD45 T cells were efficiently activated by co-incubation with CEA + tumor cells. This set of experiments demonstrates that (1) the chimeric anti-CEA receptor is preferentially triggered by membranebound and immobilized CEA but not by soluble CEA; and (2) the receptor-mediated cellular activation, as indicated by IL-2 secretion, depends on the degree of crosslinking of the receptor molecules. Whereas soluble CEA did not trigger the chimeric anti-CEA receptor, we asked whether soluble CEA may block specific receptor crosslinking by membrane-bound CEA. Therefore, we coincubated receptor-grafted MD45 T cells with CEA + LoVo colon carcinoma cells in the presence of soluble CEA and of the anti-idiotypic mAb BW2064/36, respectively. As summarized in Figure 5b , no inhibition of membrane CEA-induced cellular activation was observed in the presence of increasing concentrations of soluble CEA, even in a concentration of 25 g/ml of soluble CEA. Addition of the anti-BW431/26 idiotypic mAb, however, efficiently blocks the LoVo cell-mediated activation of grafted MD45 cells, as expected, whereas addition of an isotype-matched anti-idiotypic mAb did not (Figure 5b ). These results demonstrate that T cells grafted with the chimeric anti-CEA receptor preferentially bind to and are activated by membrane-bound CEA, even in the presence of soluble CEA in as high concentrations as of 25 g/ml.
Since the concentrations of soluble CEA in sera of colon cancer patients are in mean in the range of about 2-20 ng/ml, with few exceptions of serum levels of Ͼ4 g/ml, 9,17 soluble CEA is not expected to interfere with receptor-mediated T cell activation in colonic cancer patients.
The probability of a host-versus-graft reaction directed to xenogeneic parts of the chimeric receptor are likely to be minimized utilizing this kind of a chimeric receptor consisting exclusively of humanized domains, ie the humanized scFv fragment, the human CH2/CH3 IgG domains, and the human ␥-chain signalling unit of the Fc⑀RI receptor. Introduction of the IgG1 CH2/CH3 constant immunoglobulin domains into the extracellular moiety of the receptor, moreover, facilitates homodimerization of the receptor molecules. The potential structural homology of the chimeric receptor to the parental IgG1 due to homodimerization may account for the conserved antigen-binding properties of the scFv antibody fragment domain. On the other hand, Eshhar et al 2 demonstrated that a chimeric receptor lacking IgG constant domains is expressed in different mono-and multimeric configurations. This may be due to association of the receptor chain with the endogenous signal transduction chains of the host cell, eg CD3-chains which may affect the antigen-binding properties of the chimeric receptor.
Although so far exemplarily shown for only one receptor construct, our data raise several implications for the concept of receptor-mediated T cell targeting: (1) receptor-mediated tumor cell targeting by binding to tumor cell-associated antigen can be highly efficient even in the presence of high concentrations of soluble antigen; and (2) introduction of the immunoglobulin CH2/CH3 domains into the extracellular moiety facilitates homodimerization of the chimeric receptor on the cell membrane of the host cell.
